Suppression of REV7 enhances cisplatin sensitivity in ovarian clear cell carcinoma cells

Cancer Science

Volumn 105, Issue 5, 2014, Pages 545-552

  Niimi, Kaoru ^a   Murakumo, Yoshiki ^a,b   Watanabe, Naoki ^a   Kato, Takuya ^a   Mii, Shinji ^a   Enomoto, Atsushi ^a   Asai, Masato ^a   Asai, Naoya ^a   Yamamoto, Eiko ^a   Kajiyama, Hiroaki ^a   Shibata, Kiyosumi ^a   Kikkawa, Fumitaka ^a   Takahashi, Masahide ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Apoptosis; Chemosensitivity; Cisplatin; DNA damage; Ovarian clear cell carcinoma

Indexed keywords

CASPASE 3; CISPLATIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; REGULATOR PROTEIN; REV7 PROTEIN; UNCLASSIFIED DRUG;

ADULT; APOPTOSIS; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CELL CYCLE REGULATION; CELL PROLIFERATION; CELL PROLIFERATION ASSAY; CELL VIABILITY; CHEMOSENSITIVITY; CLEAR CELL CARCINOMA; DISEASE ASSOCIATION; DNA REPAIR; EXCISION REPAIR; FEMALE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IC 50; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; OVARIAN CLEAR CELL CARCINOMA; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING;

APOPTOSIS; CHEMOSENSITIVITY; CISPLATIN; DNA DAMAGE; OVARIAN CLEAR CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; CISPLATIN; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MAD2 PROTEINS; MALE; MICE; MICE, NUDE; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS; YOUNG ADULT;

EID: 84899922164     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12390     Document Type: Article

References (41)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
2. Kobel M, Kalloger SE, Boyd N et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 2008; 5: e232.
3. Kurman RJ, Shih IM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm. Hum Pathol 2011; 42: 918-31.
4. Mackay HJ, Brady MF, Oza AM et al. Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer. Int J Gynecol Cancer 2010; 20: 945-52.
5. Prat J. New insights into ovarian cancer pathology. Ann Oncol 2012; 23 (Suppl. 10): x111-7.
6. Chan JK, Teoh D, Hu JM, Shin JY, Osann K, Kapp DS. Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecol Oncol 2008; 109: 370-6.
7. Sugiyama T, Kamura T, Kigawa J et al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 2000; 88: 2584-9.
8. Takano M, Kikuchi Y, Yaegashi N et al. Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging. Br J Cancer 2006; 94: 1369-74.
9. Tan DS, Kaye S. Ovarian clear cell adenocarcinoma: a continuing enigma. J Clin Pathol 2007; 60: 355-60.
10. Campbell IG, Russell SE, Choong DY et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 2004; 64: 7678-81.
11. Kobel M, Kalloger SE, Carrick J et al. A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary. Am J Surg Pathol 2009; 33: 14-21.
12. Wiegand KC, Shah SP, Al-Agha OM et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 2010; 363: 1532-43.
13. Bouwman P, Jonkers J. The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. Nat Rev Cancer 2012; 12: 587-98.
14. Curtin NJ. DNA repair dysregulation from cancer driver to therapeutic target. Nat Rev Cancer 2012; 12: 801-17.
15. Johnson SW, Laub PB, Beesley JS, Ozols RF, Hamilton TC. Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines. Cancer Res 1997; 57: 850-6.
16. Murakumo Y, Roth T, Ishii H et al. A human REV7 homolog that interacts with the polymerase zeta catalytic subunit hREV3 and the spindle assembly checkpoint protein hMAD2. J Biol Chem 2000; 275: 4391-7.
17. Murakumo Y. The property of DNA polymerase zeta: REV7 is a putative protein involved in translesion DNA synthesis and cell cycle control. Mutat Res 2002; 510: 37-44.
18. Friedberg EC, Gerlach VL. Novel DNA polymerases offer clues to the molecular basis of mutagenesis. Cell 1999; 98: 413-6.
19. Murakumo Y, Ogura Y, Ishii H et al. Interactions in the error-prone postreplication repair proteins hREV1, hREV3, and hREV7. J Biol Chem 2001; 276: 35644-51.
20. Prakash S, Johnson RE, Prakash L. Eukaryotic translesion synthesis DNA polymerases: specificity of structure and function. Annu Rev Biochem 2005; 74: 317-53.
21. Cheung HW, Chun AC, Wang Q et al. Inactivation of human MAD2B in nasopharyngeal carcinoma cells leads to chemosensitization to DNA-damaging agents. Cancer Res 2006; 66: 4357-67.
22. McNally K, Neal JA, McManus TP, McCormick JJ, Maher VM. hRev7, putative subunit of hPolzeta, plays a critical role in survival, induction of mutations, and progression through S-phase, of UV((254 nm))-irradiated human fibroblasts. DNA Repair (Amst) 2008; 7: 597-604.
23. Zhao J, Liu S, Wang H et al. Mitotic arrest deficient protein MAD2B is overexpressed in human glioma, with depletion enhancing sensitivity to ionizing radiation. J Clin Neurosci 2011; 18: 827-33.
24. Rimkus C, Friederichs J, Rosenberg R, Holzmann B, Siewert JR, Janssen KP. Expression of the mitotic checkpoint gene MAD2L2 has prognostic significance in colon cancer. Int J Cancer 2007; 120: 207-11.
25. Yuan B, Xu Y, Woo JH et al. Increased expression of mitotic checkpoint genes in breast cancer cells with chromosomal instability. Clin Cancer Res 2006; 12: 405-10.
26. Li L, Shi Y, Wu H et al. Hepatocellular carcinoma-associated gene 2 interacts with MAD2L2. Mol Cell Biochem 2007; 304: 297-304.
27. Weterman MA, van Groningen JJ, Tertoolen L, van Kessel AG. Impairment of MAD2B-PRCC interaction in mitotic checkpoint defective t(X;1)-positive renal cell carcinomas. Proc Natl Acad Sci U S A 2001; 98: 13808-13.
28. Okada T, Sonoda E, Yoshimura M et al. Multiple roles of vertebrate REV genes in DNA repair and recombination. Mol Cell Biol 2005; 25: 6103-11.
29. Watanabe N, Mii S, Asai N et al. The REV7 subunit of DNA polymerase zeta is essential for primordial germ cell maintenance in the mouse. J Biol Chem 2013; 288: 10459-71.
30. Hess V, A'Hern R, Nasiri N et al. Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol 2004; 22: 1040-4.
31. Fokkema E, Groen HJ, Helder MN, de Vries EG, Meijer C. JM216-, JM118-, and cisplatin-induced cytotoxicity in relation to platinum-DNA adduct formation, glutathione levels and p53 status in human tumour cell lines with different sensitivities to cisplatin. Biochem Pharmacol 2002; 63: 1989-96.
32. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med 2002; 53: 615-27.
33. Taniguchi K, Wada M, Kohno K et al. A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res 1996; 56: 4124-9.
34. Horio M, Kato T, Mii S et al. Expression of RET finger protein predicts chemoresistance in epithelial ovarian cancer. Cancer Med 2012; 1: 218-29.
35. Kassim SK, Ali HS, Sallam MM et al. Increased bcl-2 expression is associated with primary resistance to chemotherapy in human epithelial ovarian cancer. Clin Biochem 1999; 32: 333-8.
36. Katagiri A, Nakayama K, Rahman MT et al. Loss of ARID1A expression is related to shorter progression-free survival and chemoresistance in ovarian clear cell carcinoma. Mod Pathol 2012; 25: 282-8.
37. Reles A, Wen WH, Schmider A et al. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin Cancer Res 2001; 7: 2984-97.
38. Smith G, Ng MT, Shepherd L et al. Individuality in FGF1 expression significantly influences platinum resistance and progression-free survival in ovarian cancer. Br J Cancer 2012; 107: 1327-36.
39. Yan X, Yin J, Yao H, Mao N, Yang Y, Pan L. Increased expression of annexin A3 is a mechanism of platinum resistance in ovarian cancer. Cancer Res 2010; 70: 1616-24.
40. Doles J, Oliver TG, Cameron ER et al. Suppression of Rev3, the catalytic subunit of Pol ζ, sensitizes drug-resistant lung tumors to chemotherapy. Proc Natl Acad Sci U S A 2010; 107: 20786-91.
41. Xie K, Doles J, Hemann MT, Walker GC. Error-prone translesion synthesis mediates acquired chemoresistance. Proc Natl Acad Sci USA 2010; 107: 20792-7.